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Distribution of epidermal growth factor in the kidneys of rats exposed
to amikacin. The distribution of epidermal growth factor (EGF) was
examined by immunocytochemistry in the kidneys of rats exposed to
amikacin, an aminoglycoside antibiotic causing tubular necrosis at high
dose. Five-animal groups were treated for 4 or 10 days with amikacin at
daily doses of 15, 40, 80 or 200 mg/kg. The drug was delivered i.p. twice
a day. One hour before termination, each rat received an i.p. injection
of [3H] thymidine to evaluate DNA synthesis in renal tissue. After
sacrifice, the kidneys were processed for morphological (semithin and
paraffin sections) and biochemical analysis (measurement of DNA
synthesis by [3H] thymidine incorporation in vivo). Amikacin induced
in proximal tubules a dose-related lysosomal phospholipidosis, which
was assessed by the morphometric evaluation of altered lysosomes
("myeloid bodies") on semithin section. However, frank evidence of
acute tubular necrosis was only observed in rats receiving amikacin at
a daily dose of 200 mg/kg. Concomitantly with the development of
tubular necrosis, there was a rise in the rate of cell turnover, reflected
by an increase of DNA synthesis in renal tissue. This sign of tubular
regeneration was accompanied by a redistribution of EGF immunoreac-
tivity, as revealed by immunocytochemical staining. Within renal
cortex of control rats, EGF immunoreactivity predominantly appeared
in distal tubules and collecting ducts (97% of examined tubular sec-
tions). In contrast, in treated animals where the renal cortex displayed
evidence of tubular necrosis/regeneration, EGF immunoreactivity was
frequently associated with proximal tubules (more than 30% of exam-
ined tubular sections, as compared to 3% in controls). This change in
the topography of EGF immunoreactivity suggests that the growth
factor might be involved in the process of tissue repair consecutive to
drug-induced tubular necrosis.
Although the kidney is prone to hypoxic or nephrotoxic insult
eventually resulting in tubular necrosis [1], injury is usually
followed by a tissue repair reaction which tends to compensate
for the loss of tubular epithelium. Renal tubular regeneration is
a well known phenomenon in pathology [2], and has been
characterized both qualitatively and quantitatively in experi-
mental studies on animals exposed to various nephrotoxins [3,
4]. It involves an increase of cell turnover, occurring primarily,
but not exclusively, in the area of tubular epithelium which has
suffered injury [5—71. Frequently, tubular regeneration is also
associated with a transient dedifferentiation of epithelial cells,
and is particularly conspicuous in the proximal sections of the
nephron [8—10]. In addition, the stimulation of epithelial cells
proliferation is often accompanied by a mild fibroblastic hyper-
plasia in renal interstitium [10, 11].
In contrast with the renal compensatory growth observed
after unilateral nephrectomy [12, 14], tubular regeneration has
remained mostly unexplored with regard to its mechanism.
Several experimental facts suggest, however, that the process is
submitted to a biological control, probably involving endoge-
nous regulators. First, the increase of cell proliferation must
involve a transition from quiescence (GO phase) to 01 phase of
the cell cycle, since in the normal state the rate of cell turnover
is very low in renal tissue [15]. Second, the extent of the
proliferative response remains commensurate with the degree
of tubular injury and does not entail detectable increase in renal
mass [16, 17]. Third, the wave of cell divisions and the apparent
loss of differentiation which follow tubular necrosis are gener-
ally transient, the kidney returning to its basal cell kinetics and
the tubular cells regaining their differentiation characters after
repair of the lesions [8, 9]. Finally, the proliferative activity
associated with tubular regeneration seems to occur indepen-
dently of circulating factors [18].
During the last decade the concept has emerged that the
division and differentiation of eucaryotic cells are controlled by
polypeptide growth factors 119, 20] acting in paracrine or
autocrine fashion. For the kidney in particular, several growth
factors have been proposed to regulate cell proliferation [21].
Recently, two studies have shown that the administration of
epidermal growth factor (EGF) enhances tubular regeneration
and accelerates the recovery of normal renal function following
postischemic acute renal failure [22, 23]. Thus, the present
study examines the distribution of EGF immunoreactivity in
renal tissue after treatment with amikacin, a nephrotoxic ami-
noglycoside antibiotic.
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Animals and treatment
Female Sprague-Dawley rats were used throughout the
study. The animals were purchased from a commercial breeding
farm (Iffa-Credo, l'Arbresle, France) and allowed one week of
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acclimatation before starting the treatment. During the acclima-
tation and treatment periods, the rats were maintained in an
animal facility with a regular 12-hour light/dark cycle, and had
free access to tap water and rodent chow (type A04, U.A.R.,
Villemoisson-sur-Orge, France). The weight of the animals,
measured prior to the first amikacin dosing, was found roughly
similar for all individuals (mean weight: 204 g, with less than 5%
deviation from that value).
Amikacin solutions were prepared in 0.9% NaCl from the
ready-to-use preparation available for clinical practice
(Amukin®, Laboratoires Bristol Benelux, Brussels). Five-ani-
mal groups were treated for 4 or 10 days with amikacin at daily
doses of 15, 40, 80 or 200 mg/kg. The drug was delivered i.p. in
two daily injections (9:00 a.m. and 6:00 p.m.), the volume of
injected solution (approx. 0.5 ml) being adjusted each time
according to body weight. Control animals received an equiv-
alent amount of 0.9% NaC1 following the same protocol.
One hour prior to sacrifice, 200 Ci of [methyl-3H] thymidine
(40 Ci/mmol, Amersham International, Amersham, UK) was
injected i.p. to each rat, for the measurement of DNA synthesis
in renal tissue.
Sacrifice and sampling of renal tissue
The animals were terminated by decapitation 15 hours after
the last drug administration. Following laparotomy, the kidneys
were quickly exposed. After bisection, one half of the right
kidney was immersed in Duboscq-Brazil fixative for light mi-
croscopy. Renal cortex was separated from the other half by
sharp dissection and diced in 1 mm3 blocks after immersion in
glutaraldehyde fixative for electron microscopy (2% glutaralde-
hyde in 0.1 M cacodylate buffer, pH 7.4). The left kidney was
also bisected and the renal cortex separated by dissection.
Kidney cortex from the left kidney was snap-frozen in dry ice
and stored at —20°C until biochemical analysis.
Preparation of specimens for morphological analysis
Paraffin sections. Kidney samples fixed in Duboscq-Brazil
fluid were rinsed twice in 70% ethanol and once in butanol.
After proper dehydration following routine procedure, the
samples were embedded in Paraplast plus® paraffin. Sections of
4 to 5 j.m thickness were cut on a Reichert Autocut 2040
microtome equipped with a glass knife, and mounted on glass
slides. For standard morphological examination, renal tissue
was stained with periodic acid-Schiff, hemalun and luxol fast
blue.
Morphological demonstration of EGF immunoreactivity.
EGF immunoreactivity was revealed on paraffin tissue section
by an immunogold-silver staining procedure, as described pre-
viously [24]. Dewaxed paraffin sections were rehydrated with
phosphate-buffered saline, pH 7.4 (PBS) and pretreated for 20
minutes with 5% normal goat serum in the same buffer, to
prevent nonspecific adsorption. Thereafter, the sections were
incubated overnight at 4°C in presence of rabbit anti-mouse
EGF (BioMakor, Rehovot, Israel) (1: 150 dilution in PBS con-
taining 5% normal goat serum). Treatment with the primary
antibody was followed by a one hour exposure to goat anti-
rabbit IgG antiserum adsorbed on 5-nm colloidal gold particles
(Auro Probe LM, Janssen Biotech, Olen, Belgium) (1:50 dilu-
tion in the same buffer). After several rinses in PBS and distilled
water to eliminate the excess of labeled antibody, immunogold
labeling was enhanced by short-term treatment (6 to 10 mm)
with silver staining reagent (Inten SE M, Janssen Biotech,
Olen, Belgium). Finally, silver enhancement was arrested by
rinsing in distilled water.
According to the supplier's specification, polyclonal anti-
EGF antibody was raised against highly purified EGF from
mouse submaxillary glands, thus minimizing the risk of cross
reactions. To check the specificity of the immunocytochemical
labeling, the primary antibody was replaced by non-immune
rabbit serum or by anti-EGF antiserum preincubated with an
excess of antigen (70 g/ml purified EGF). These controls were
negative. In addition, we verified that anti-EGF antiserum gave
positive staining in sections of mouse submaxillary gland.
Finally, the same anti-EGF antiserum was used to reveal EGF
immunoreactivity in mouse renal tissue. The staining pattern
was similar to that reported in this study for the kidney of
control rats.
Semithin sections. Renal cortex specimens were kept in
buffered glutaraldehyde solution for four hours at 4°C. The
blocks were thereafter rinsed overnight in 0.1 M cacodylate
buffer, pH 7.4 containing 4% sucrose. After three rinses in
buffered sucrose solution, the blocks were postfixed in 2%
osmium tetroxide (2% 0s04 in 0.04 M veronal-acetate buffer,
5.6% sucrose, pH 7.4), dehydrated in graded acetone solutions
and rinsed in propylene oxide. The samples were embedded in
Epon 812 and semithin sections (1 to 2 m thick) were cut with
a glass knife on a LKB type 4801A ultramicrotome. Sections
were mounted on glass slides and stained with toluidine blue
before examination.
Morphological analysis
Semiquantitative assessment of drug-induced injury. Suble-
thal alterations and tubular necrosis associated with amikacin
nephrotoxicity were submitted to single-blind evaluation fol-
lowing an approach similar to that developed previously for the
study of cisplatin nephrotoxicity [171, except that only proximal
tubules were considered. Briefly, one paraffin section per
experimental animal was examined by an observer who was
kept unaware of the treatment. Twenty 0.084 mm2 fields were
scanned at 400-fold magnification and morphological abnormal-
ities in proximal tubules located in each field were graded along
an arbitrary scale: 0, no departure from normal morphology as
observed in control animals; 1, abnormal vacuolization, PAS-
positive inclusions or focal cell necrosis; 2, at least one necrotic
tubular section (more than half of the necrotic tubular section(s)
remaining identifiable); 3, same as 2, but less than half of the
necrotic section(s) remaining identifiable; 4, totally necrotic
tubule(s) of unindentifiable origin. For each animal, an average
score was calculated to express the level of tubular injury.
Morphometric evaluation of lysosomes in proximal tubules.
The relative size of lysosomes in proximal tubules was evalu-
ated by a computer-aided morphometric approach, using a
software specifically designed for color analysis and morphom-
etry (systeme d'Analyses Microscopiques a Balayage Automa-
tique, SAMBA, Alcatel TITN Answare, Grenoble, France),
and relied on the fact that, in semithin sections, lysosomes
exhibit a blue coloration after staining with toluidine blue. One
tissue section per animal was examined at 400-fold magnifica-
tion on a Zeiss Axioplan light microscope equipped with a
high-resolution JVC KY. 15 color video camera. Approximately
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Fig. 1. Morphological alterations and tubular necrosis induced by amikacin in rat kidney. A and B illustrate the light microscopic appearance of
renal cortex on semithin sections obtained from control and treated (40 mg/kg day, 4 days) animals, respectively. After amikacin administration,
lysosomes (arrowheads) increased in size and exhibited a heterogenous content (x 540). C through F are paraffin sections of kidneys from treated
rats. C. PAS (+) vacuoles (arrowhead) in a proximal tubular cell (80 mg/kg day amikacin, 10 days). D. Focal cell necrosis (pycnotic nucleus,
arrow) in a proximal tubule (80 mg/kg day amikacin, 4 days). E. Mitotic figure (arrow) in a proximal tubule (80 mg/kg day amikacin, 4 days).
F. Tubular necrosis (NT). The arrow indicates a mitotic figure in a neighboring tubular section (200 mg/kg . day amikacin, 10 days) (X 645).
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Daily dose of amikacin, mg/kg
Fig. 2. Increase of size of lysosomes in kidney proximal tubules of rats
treated with amikacin (4 days, closed circles). The total area occupied
by lysosomes in proximal tubular cells was evaluated by morphometric
approach and expressed relative to tubular sections (see Methods
sections). Each symbol refers to the mean value calculated for the
group (N 5), the vertical bar indicating the standard deviation. The
open circle corresponds to control animals. Statistical difference be-
tween data (P < 0.05, Student's t-test) is shown by the asterisks (values
significantly higher than mean control value) and the star (value
significantly higher than all other values).
10 fields were successively scanned by the camera and proc-
essed by a MVP-AT/NP imaging system implemented in an
IBM-compatible microcomputer (Compaq type AT 386/25).
Proximal tubular sections picked at random for morphometric
analysis were delineated in interactive mode and their area was
computed. In each tubular section, lysosomes were detected by
setting a lower threshold in gray levels (green channel) and the
aggregated area of these organelles was calculated relative to
the area of the corresponding tubular section. Approximately
25,000 tm2 of tubular sections were thus analyzed per experi-
mental animal.
Measurement of DNA synthesis in renal tissue
The rate of DNA synthesis was evaluated by measuring the
extent of [3H] thymidine incorporation into renal tissue DNA,
as described previously [25]. Briefly, renal tissue samples were
homogenized in distilled water and DNA was isolated by acid
precipitation [26]. The concentration and radioactivity of the
nucleic acid were measured by colorimetry [27] and liquid
scintillation counting, respectively. The amount of incorporated
[3H] thymidine was inferred from DNA specific radioactivity.
Statistical analysis
The data were compared statistically on the basis of Stu-
Results
dent's t-test.
Effect of treatment on animal growth and viability
Even at high dose, amikacin administration was well toler-
ated by the experimental animal. No rat was lost during the
treatment period or even showed overt evidence of systemic
toxic reaction. During the 10 day period of aminoglycoside
dosing, a mean weight gain of 8.7% was observed in the animals
receiving a daily dose of 200 mg/kg amikacin (8.4% in controls).
Lysosomal phospholipidosis and histopathological alterations
The kidneys of treated animals were examined by light
microscopy to disclose signs of sublethal alterations and of
drug-induced tubular necrosis. After four days of amikacin
administration proximal tubular cells already exhibited the
morphological abnormality typical of aminoglycoside-induced
phospholipidosis [28—30], as revealed by examination of semi-
thin sections of renal cortex. Lysosomes appeared enlarged,
irregular in shape and showed a heterogenous content (Fig. 1 A
and B). The global size of the lysosomes, evaluated by mor-
phometric analysis, increased in parallel with the daily dosage
of amikacin (Fig. 2).
Although signs of aminoglycoside-induced phospholipidosis
(particularly the heterogeneity of lysosomal content) were
already apparent in animals treated with the lowest dose (15
mg/kg) of amikacin, frank tubular necrosis was only observed in
paraffin sections of kidneys from animals treated for 10 days
with 200 mg/kg amikacin (Fig. lF). At lower doses and in
animals treated for four days, proximal tubules displayed mild
alterations, such as an accumulation of PAS(+) vacuoles in
epithelial cells (Fig. 1C), focal cell necrosis (Fig. lD) and
evidence of increased cell turnover (frequent occurrence of
mitotic figures; Fig. 1E).
Proliferative response and distribution of EGF
immunoreactivity
Figure 3 shows the rate of DNA synthesis measured in the
renal cortex tissue of rats treated with various doses of amika-
cm. Consistently with the fact that mitotic figures appeared
repeatedly in proximal tubules of treated rats, amikacin admin-
istration led to a stimulation of cell proliferation in the kidney
with a concomitant increase of DNA synthesis. At low doses
and/or after the four-day administration, amikacin only exerted
a minimal effect, but the aminoglycoside produced a more
substantial increase of DNA synthesis (more than three-fold the
mean control value) when given at high doses and/or for 10
days. Although the histological nature of proliferating cells was
not determined in the present experiments, previous studies
[16] on the proliferative response occurring in rat kidney after
amikacin administration indicate that this reaction primarily
involves proximal tubular cells, with only a minor contribution
of interstitial cells.
When the rate of DNA synthesis was plotted against the
degree of drug-induced morphological alterations and tubular
necrosis, the regression analysis gave a high correlation coeffi-
cient (r = 0.93), indicating a parallelism between tissue injury
and the proliferative response (Fig. 4).
As illustrated in Figure 5, the immunocytochemical proce-
dure clearly demonstrated the presence of anti-EGF reactive
material within epithelial cells of renal tubules. In control
animals, EGF immunoreactivity was mostly confined to distal
tubules and collecting ducts located in the inner stripe of outer
medulla, but could also be found occasionally within renal
cortex, associated with distal tubules (Fig. 5 A and B). Among
tubular sections reacting positively with anti-EGF, few (3% or
less of stained sections) belonged to the proximal section of the
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Fig. 4. Relationship between the rate of DNA synthesis (abscissa) and
the degree of tubular injury (sublethal alterations and tubular necrosis
evaluated on paraffin sections, Methods) (ordinate). The analysis was
performed on animals treated for 10 days with daily doses of 15 mg/kg
amikacin (0), 40 mg/kg amikacin (•), 80 mg/kg amikacin (U) and 200
mg/kg amikacin (A). The correlation coefficient r was calculated by
regression analysis; r = 0.93.
nephron. No drastic change in the pattern of EGF immunoreac-
tivity was found in treated animals, up to 80 mg/kg day. After
the four-day treatment with 200 mg/kg day amikacin, distal
tubules located in renal cortex exhibited strong positive reac-
tion after immunocytochemical staining (Fig. 5 C and D).
Strikingly, in animals dosed for 10 days with amikacin at 200
mg/kg day, the topography of EGF immunoreactivity ap-
peared drastically modified within kidney cortex, since a size-
able proportion (>30%) of stained section were identified as
proximal tubules (Fig. 5 E and F). In addition, the intracellular
distribution of anti-EGF reactive material was different in cells
of proximal tubules, as compared to those of distal tubules and
collecting ducts. Whereas in the latter, the immunocomplex
seemed to occupy the whole cytoplasm (Fig. SD), in the former,
EGF immunoreactivity was predominantly located in the basal
part of epithelial cells (Fig. SF).
Discussion
A variety of nephrotoxic compounds are known to cause
acute tubular necrosis [31—34]. In this study, amikacin was
selected as a model because it belongs to the group of amino-
glycoside antibiotics, drugs for which the mechanism of neph-
rotoxicity is well documented [reviewed in 35—371.
Aminoglycosides accumulate within proximal tubular cells
[38] where they induce a lysosomal phospholipidosis [9, 28—30,
39], this metabolic disturbance resulting from an impairment of
phospholipid catabolism [40—42]. The causal relationship be-
tween phospholipid accumulation in proximal tubules and the
ensuing tubular necrosis is particularly well substantiated by
the effect of protective agents [43—47], namely anionic polypep-
tides which both prevent the development of aminoglycoside-
induced phospholipidosis and alleviate tubular injury. From
comparative in vitro and in vivo studies, it has become clear
that different aminoglycoside derivatives, varying in their pro-
pensity to interfere with phospholipid enzymatic hydrolysis, are
also endowed with a different nephrotoxic potential [29, 48, 49].
In this respect, amikacin has been demonstrated to behave as a
mild nephrotoxin.
Therefore, the use of amikacin as a model to study tubular
regeneration after nephrotoxic tissue injury presents further
advantage. The administration of ascending doses enables one
to create the whole spectrum of renal insult (from mere cyto-
logical abnormality to frank tubular necrosis). However, it
becomes feasible to differentiate early metabolic alterations
from cell death. Indeed our results show that, at low doses of
amikacin, the proximal tubule already shows evidence of drug-
induced phospholipidosis, whereas the administration of higher
doses is necessary to obtain tubular necrosis.
This point appears particularly crucial since, in amikacin-
treated rats, a sizeable change in the localization of EGF
immunoreactivity was not observed concomitantly with the
formation of myeloid bodies (the morphological manifestation
of the lysosomal phospholipidosis), but only occurred in the
kidneys showing evidence of tubular necrosis and regeneration.
The staining pattern that we obtained after EGF immunolo-
calization in the kidneys of control rats did not show major
differences with that appearing in the previous studies of Salido
et al on the mouse kidney [50, 51], except for the presence of
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Fig. 3. Rate of DNA synthesis in renal cortex
tissue of rats treated with amikacin. DNA
synthesis was estimated by the extent of [3H]
thymidine incorporation into DNA (Methods).
Each column refers to the mean value of each
group (N = 5), with the standard deviation
40 80 shown by the vertical bar. Statistical difference(P < 0.05, Student's test) between treated and
control (c) rats is indicated by asterisks.
>.
C
CD
I—
100 200 300 400 500 600
Fig. 5. Immunocytochemical demonstration of EGF immunoreactivity in the kidneys of control (a and b) and treated (c—f) rats. Consecutive
paraffin sections of renal tissue were either stained by conventional histological method (periodic acid-Schiff, hemalun and luxol fast blue, a, c, e)
or processed to reveal the presence of anti-EGF reactive material (b, d, f). a and b. Presence of EGF immunoreactivity in distal tubules. c and d.
Strong positive reaction of distal tubular cells with anti-EGF antibody (rat treated with 200 mg/kg amikacin, 4 days). The arrows point to the macula
densa, which does not show any immunolabeling. e and f. EGF immunoreactivity associated with proximal tubules (rat treated with 200 mg/kg
amikacin, 10 days).
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EGF-like immunoreactive material in collecting ducts, which
was not reported by these authors. Although an explanation for
that apparent discrepancy still remains to be found, we think
that it is more likely to originate from a species difference rather
than from artifacts in our immunocytochemical procedure.
Indeed, the occurrence of EGF in collecting ducts has been
recently confirmed at the ultrastructural level, by using electron
microscopy immunocytochemistry (Toubeau et al, manuscript
in preparation).
The redistribution of EGF immunoreactivity reported here
appears consistent with other studies and provides additional
evidence for a role of EGF as a positive mediator during the
tissue repair of tubular necrosis. EGF receptors have been
identified on the basolateral membrane of proximal tubular cells
[52, 53]. Moreover, established epithelial cell lines of renal
origin and tubular cells in primary cultures respond to the
mitogenic effect of EGF in vitro [52, 54]. Finally, the adminis-
tration of EGF has been reported recently to promote the repair
of renal tubules after hypoxic or nephrotoxic injury [22, 23, 55].
At this stage of the study, the interpretation of our observa-
tions still remains difficult, since the immunocytochemical
approach that we used does not give any information on the
molecular structure and the origin of the immunoreactive ma-
terial. Although substantial EGF synthesis has been demon-
strated in the kidney by in situ hybridization [56], the growth
factor is produced within this organ as a high molecular weight
precursor, which under normal circumstances does not appear
to be processed to give the low molecular weight form of EGF
[57]. Furthermore, in the normal kidney, EGF exists as a
membrane bound protein [51, 58] predominantly located in the
thick ascending limb of Henle and in distal convoluted tubules.
Thus, the origin of the EGF immunoreactivity which is found at
the level of proximal tubules during tubular regeneration re-
mains to be uncovered. It is worth pointing out, however, that
urinary EGF exclusively originates from the kidney [59—61] and
that serum level of EGF is very low, two facts which argue
against an extrarenal (for example, the salivary glands) origin
for the EGF present in renal parenchyma.
Additional questions remain to be answered concerning the
high incidence of proximal tubules reacting positively with
anti-EGF antibody during tubular regeneration. Recently, Nor-
man et al [23] have demonstrated an increased binding of
exogenous 1251-EGF in renal tissue during the episode of tissue
repair which follows ischemic acute tubular necrosis. This
observation leads us to postulate that the EGF immunoreactiv-
ity exhibited by proximal tubules might be due to the interaction
of endogenous EGF with the receptors present at the surface of
proximal tubular cells and might be related to a phenomenon of
receptor upregulation [62].
Whether or not there is an increase of EGF concentration
within renal tissue during tubular regeneration remains an open
issue. Recently, Safirstein et al [63, 64] have examined by
hybridization techniques the level of preproEGF mRNA in the
kidneys of rats after cisplatin administration or induction of
renal ischemia, and found a decline in the amount of mRNA,
concomitant with the acute renal failure resulting from nephro-
toxic or hypoxic injury. This finding suggests that the regener-
ative response of the kidney is not accompanied by an increased
de novo synthesis of EGF. Moreover, these authors demon-
strated in the experimental animals experiencing renal dysfunc-
tion a decline of EGF urinary excretion and increased EGF
binding to surface receptors of renal tubular cells. Although
renal tubular regeneration appears associated with a decreased
expression of the gene coding for preproEGF (or an increased
degradation of the corresponding mRNA), that does not ex-
clude the possibility that EGF might be involved as a positive
mediator in this process. For instance, during the proliferative
response which follows tubular necrosis, mature EGF could be
released in a diffusible form from enzymatic processing of the
membrane-bound high molecular weight precursor. Indeed, in
vitro proteolysis of EGF precursor purified from renal tissue
has been shown to result in the appearance of a smaller
polypeptide of a size similar to that of mature EGF and reacting
with anti-EGF antiserum [65].
Taken altogether, the experimental facts available to date
suggest that, during tubular regeneration, EGF precursor might
be converted at distal tubular level into a low molecular weight,
diffusible form and attain proximal tubules through the intersti-
tial space. Although this concept is still highly speculative, it
deserves further experimental probing.
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